Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
HIV Clinical Trials|July 28, 2015
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexityKaren T Tashima, Katie R Mollan, Lumine Na, et al.
Bioorganic & Medicinal Chemistry|August 1, 2009
A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell linesPo-Shen Pan, Robert C Vasko, Stephanie A Lapera, et al.
HIV Clinical Trials|December 17, 2013
Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trialValerianna K Amorosa, Anne Luetkemeyer, Minhee Kang, et al.
AIDS (London, England)|May 6, 2008
Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA declineJ Michael Kilby, Ha Youn Lee, J Darren Hazelwood, et al.
The Journal of Infectious Diseases|January 28, 2010
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failureRoger Paredes, Christina M Lalama, Heather J Ribaudo, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 24, 2003
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Hepatology (Baltimore, Md.)|October 24, 2006
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Marion G Peters, Janet Andersen, Patrick Lynch, et al.
The Journal of Infectious Diseases|February 14, 2008
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjectsDaniel R Kuritzkes, Christina M Lalama, Heather J Ribaudo, et al.
Annals of Internal Medicine|November 24, 2015
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled TrialKaren T Tashima, Laura M Smeaton, Carl J Fichtenbaum, et al.
Journal of Clinical Microbiology|May 31, 2002
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliterLisa M Demeter, Ronald J Bosch, Robert W Coombs, et al.
Pageof 6